Results 81 to 90 of about 13,248 (184)

Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients

open access: yes, 2021
Avibactam is a β-lactamase inhibitor that is combined with aztreonam against Enterobacterales co-expressing serine- and metallo-β-lactamases (MBL). Optimal dosing of aztreonam with avibactam is not well-defined in critically ill patients and contingent ...
Tiseo, Giusy   +9 more
core   +1 more source

Guidelines for Essential Trauma Care: Second Edition (2026)

open access: yesWorld Journal of Surgery, Volume 50, Issue 6, Page 1409-1450, June 2026.
Injury is a major cause of death and disability globally, with the highest burden in low‐ and middle‐income countries (LMICs). Strengthening the organization and planning for trauma care (care of the injured) can improve care and lower mortality. In 2004, the International Association for Trauma Surgery and Intensive Care (IATSIC) and the World Health ...
Charles Mock   +41 more
wiley   +1 more source

The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β -lactamase in Enterobacter cloacae

open access: yes, 2013
Christine Miossec, Monique Claudon, Premavathy Levasseur, Michael T Black Novexel, Romainville, France Abstract: Induction of ampC β-lactamase expression can often compromise antibiotic treatment and is triggered by several β-lactams (such as ...
Black MT   +3 more
core  

Image_1_In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China.tif

open access: yes, 2021
ObjectivesThe aim of this work was to investigate the activity of ceftazidime–avibactam (CZA) and aztreonam–avibactam (AZA) against bloodstream infections caused by carbapenem-resistant organisms (CROs).MethodsNon-duplicate CROs, including 56 carbapenem ...
Jinru Ji (4023998)   +7 more
core   +1 more source

In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against multidrug-resistant Klebsiella pneumoniae and Escherichia coli

open access: yes, 2019
Background: Increasing resistance to broad-spectrum cephalosporin and carbapenem in Enterobacteriaceae makes it challenging to select appropriate antibiotics. There are limited treatment options for these pathogens.
이승철
core   +1 more source

AmpC termelő Gram-negatív baktériumok in vitro ceftazidim/avibactam érzékenységének vizsgálata korongdiffúziós módszerrel

open access: yes, 2016
Diplomadolgozatomat a DE Orvosi Mikrobiológiai Intézetében végeztem. 2015. májustól 2016. január végéig gyűjtött Enterobacteriaceae család tagjainál (AmpC, valamint AmpC és ESBL termelő) vizsgáltam in vitro körülmények között a ceftazidim/avibactam ...
Dull, Zsuzsánna Eszter
core  

Synergistic Effect of Ceftazidime-Avibactam with Aztreonam on Carbapenemase-Positive Klebsiella pneumoniae MBL+, NDM+ [PDF]

open access: yes
Mateusz Szymański,1,2 Małgorzata M Skiba,2 Małgorzata Piasecka,2 Alina Olender3 1Human Anatomy Department, Medical University, Lublin, Poland; 2Intensive Care Unit, Stefan Cardinal Wyszyński District Specialist Hospital ...
Szymański M   +3 more
core  

Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model [PDF]

open access: yesКлиническая микробиология и антимикробная химиотерапия
Objective. To study pharmacodynamics of meropenem alone and in combination with avibactam in an in vitro dynamic model; to evaluate effectiveness of meropenem against K.
Strukova E.N., golikova-mv.
doaj   +1 more source

Antimicrobial Resistance Profiles of Pseudomonas aeruginosa in a Korean Community Hospital: In Vitro Activity of Ceftazidime-Avibactam and Other Agents

open access: yesPolish Journal of Microbiology
The novel antibiotic ceftazidime-avibactam was introduced in Korea in 2023. This study evaluated the in vitro susceptibility of Pseudomonas aeruginosa isolates from a community-based hospital to various antibiotics, including ceftazidime-avibactam.
Lee Hyo-Jin   +6 more
doaj   +1 more source

Pharmacodynamic modelling of β-lactam/β-lactamase inhibitor checkerboard data: illustration with aztreonam–avibactam

open access: yes, 2019
International audienceOBJECTIVES: Checkerboard experiments followed by fractional inhibitory concentration (FIC) index determinations are commonly used to assess in vitro pharmacodynamic interactions between combined antibiotics, but FIC index cannot be ...
Grégoire, N.   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy